Ignite Creation Date:
2025-12-24 @ 7:58 PM
Ignite Modification Date:
2026-01-05 @ 5:54 PM
Study NCT ID:
NCT06589804
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2024-09-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Head and Neck Squamous Cell Carcinoma | View |
| None | Metastatic Hypopharyngeal Squamous Cell Carcinoma | View |
| None | Metastatic Laryngeal Squamous Cell Carcinoma | View |
| None | Metastatic Oral Cavity Squamous Cell Carcinoma | View |
| None | Metastatic Oropharyngeal Squamous Cell Carcinoma | View |
| None | Recurrent Head and Neck Squamous Cell Carcinoma | View |
| None | Recurrent Hypopharyngeal Squamous Cell Carcinoma | View |
| None | Recurrent Laryngeal Squamous Cell Carcinoma | View |
| None | Recurrent Neck Squamous Cell Carcinoma of Unknown Primary | View |
| None | Recurrent Oral Cavity Squamous Cell Carcinoma | View |
| None | Recurrent Oropharyngeal Squamous Cell Carcinoma | View |
| None | Refractory Head and Neck Squamous Cell Carcinoma | View |
| None | Refractory Hypopharyngeal Squamous Cell Carcinoma | View |
| None | Refractory Laryngeal Squamous Cell Carcinoma | View |
| None | Refractory Oral Cavity Squamous Cell Carcinoma | View |
| None | Refractory Oropharyngeal Squamous Cell Carcinoma | View |
| None | Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC … | View |
| None | Stage IV Hypopharyngeal Carcinoma AJCC v8 | View |
| None | Stage IV Laryngeal Cancer AJCC v8 | View |
| None | Stage IV Lip and Oral Cavity Cancer AJCC v8 | View |
| None | Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | View |
Keywords: